Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 91703-91710 |
| Number of pages | 8 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 53 |
| Publication status | Published - 2017 |
Fingerprint
Keywords
- Brentuximab vedotin
- Hodgkin's lymphoma
- Long-term response
- Real life
- Stem cell transplantation
- brentuximab vedotin
- CD30 antigen
- acute myeloid leukemia
- adult
- adult respiratory distress syndrome
- aged
- allogeneic stem cell transplantation
- Article
- cancer recurrence
- clinical practice
- disease free survival
- disease severity
- drug dose reduction
- drug efficacy
- drug response
- drug safety
- drug tolerability
- female
- follow up
- histopathology
- Hodgkin disease
- human
- incidence
- Italy
- major clinical study
- male
- multiple cycle treatment
- neutropenia
- observational study
- overall survival
- pancreatitis
- pancytopenia
- peripheral neuropathy
- personal experience
- progression free survival
- respiratory failure
- retrospective study
- sensory neuropathy
- thrombocytopenia
- treatment duration
Cite this
Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. / Pellegrini, C.; Broccoli, A.; Pulsoni, A.; Rigacci, L.; Patti, C.; Gini, G.; Mannina, D.; Tani, M.; Rusconi, C.; Romano, A.; Vanazzi, A.; Botto, B.; Santoro, A.; Hoaus, S.; Rigolin, G.M.; Musto, P.; Mazza, P.; Molica, S.; Corradini, P.; Fama, A.; Gaudio, F.; Merli, M.; Ronconi, F.; Gritti, G.; Vallisa, D.; Tosi, P.; Liberati, A.M.; Pinto, A.; Pavone, V.; Gherlinzoni, F.; Bianchi, M.P.; Volpetti, S.; Trentin, L.; Goldaniga, M.C.; Bonfichi, M.; Renzo, A.D.; Schiavotto, C.; Spina, M.; Carella, A.M.; Stefoni, V.; Argnani, L.; Zinzani, P.L.
In: Oncotarget, Vol. 8, No. 53, 2017, p. 91703-91710.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
AU - Pellegrini, C.
AU - Broccoli, A.
AU - Pulsoni, A.
AU - Rigacci, L.
AU - Patti, C.
AU - Gini, G.
AU - Mannina, D.
AU - Tani, M.
AU - Rusconi, C.
AU - Romano, A.
AU - Vanazzi, A.
AU - Botto, B.
AU - Santoro, A.
AU - Hoaus, S.
AU - Rigolin, G.M.
AU - Musto, P.
AU - Mazza, P.
AU - Molica, S.
AU - Corradini, P.
AU - Fama, A.
AU - Gaudio, F.
AU - Merli, M.
AU - Ronconi, F.
AU - Gritti, G.
AU - Vallisa, D.
AU - Tosi, P.
AU - Liberati, A.M.
AU - Pinto, A.
AU - Pavone, V.
AU - Gherlinzoni, F.
AU - Bianchi, M.P.
AU - Volpetti, S.
AU - Trentin, L.
AU - Goldaniga, M.C.
AU - Bonfichi, M.
AU - Renzo, A.D.
AU - Schiavotto, C.
AU - Spina, M.
AU - Carella, A.M.
AU - Stefoni, V.
AU - Argnani, L.
AU - Zinzani, P.L.
N1 - Export Date: 21 February 2018 Correspondence Address: Zinzani, P.L.; Institute of Hematology 'L. e A. Seràgnoli', University of BolognaItaly; email: pierluigi.zinzani@unibo.it
PY - 2017
Y1 - 2017
N2 - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. © Pellegrini et al.
AB - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. © Pellegrini et al.
KW - Brentuximab vedotin
KW - Hodgkin's lymphoma
KW - Long-term response
KW - Real life
KW - Stem cell transplantation
KW - brentuximab vedotin
KW - CD30 antigen
KW - acute myeloid leukemia
KW - adult
KW - adult respiratory distress syndrome
KW - aged
KW - allogeneic stem cell transplantation
KW - Article
KW - cancer recurrence
KW - clinical practice
KW - disease free survival
KW - disease severity
KW - drug dose reduction
KW - drug efficacy
KW - drug response
KW - drug safety
KW - drug tolerability
KW - female
KW - follow up
KW - histopathology
KW - Hodgkin disease
KW - human
KW - incidence
KW - Italy
KW - major clinical study
KW - male
KW - multiple cycle treatment
KW - neutropenia
KW - observational study
KW - overall survival
KW - pancreatitis
KW - pancytopenia
KW - peripheral neuropathy
KW - personal experience
KW - progression free survival
KW - respiratory failure
KW - retrospective study
KW - sensory neuropathy
KW - thrombocytopenia
KW - treatment duration
M3 - Article
VL - 8
SP - 91703
EP - 91710
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 53
ER -